Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 8/20 | 0.67 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868658 | 0.90 | CHRM4 (0.66) | CHRM4MCHR1MEN1KMT2ACHRM1 | |
| SCHEMBL6705916 | 0.89 | CHRM4 (0.69) | CHRM4MCHR1MEN1KMT2ACHRM1 | |
| SCHEMBL6705871 | 0.87 | CHRM4 (0.53) | CHRM4MCHR1CHRM1CHRM2CHRM5 | |
| SCHEMBL6705886 | 0.87 | CHRM4 (0.55) | CHRM4MCHR1CHRM1CHRM2CHRM5 | |
| SCHEMBL6221442 | 0.84 | MCHR1 (0.55) | CHRM4MCHR1CHRM1TSHRPOLB | |
| SCHEMBL6705906 | 0.81 | MCHR1 (0.52) | CHRM4MCHR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18825718 | 0.80 | CHRM4 (1.00) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6704534 | 0.80 | L3MBTL3 (0.59) | CHRM4MCHR1CHRM1CYP2D6HTR2A | |
| SCHEMBL6704726 | 0.80 | MAPT (0.56) | CHRM4MCHR1CHRM1CYP2D6HTR2A | |
| SCHEMBL6706014 | 0.79 | CHRM4 (0.54) | CHRM4MCHR1CHRM1CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | CHRM4 467/4885MCHR1 2/4885MEN1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.